<DOC>
	<DOCNO>NCT00540982</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , vinorelbine , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This pilot trial study side effect best dose vinorelbine treating patient advance solid tumor respond treatment liver dysfunction .</brief_summary>
	<brief_title>Vinorelbine Treating Patients With Advanced Solid Tumors That Have Not Responded Treatment Liver Dysfunction</brief_title>
	<detailed_description>OBJECTIVES : - To correlate indocyanine green lidocaine metabolism vinorelbine ditartrate pharmacokinetics patient advance , refractory solid tumor vary degree liver dysfunction . - To determine pharmacokinetics vinorelbine ditartrate patient . - To test plan dose adjustment vinorelbine ditartrate administration patient . OUTLINE : Patients stratify accord extent clinical liver dysfunction ( normal v mild v moderate v severe ) . Patients receive dose-adjusted vinorelbine ditartrate IV 10 minute weekly absence disease progression unacceptable toxicity . Patients achieve objective complete response receive 2 additional course study therapy . Patients undergo blood sample collection periodically study pharmacokinetic pharmacodynamic correlative study . Blood also collect patient receive lidocaine IV push indocyanine green ( ICG ) IV push . Samples analyze whole blood plasma concentration vinorelbine ditartrate metabolite high performance liquid chromatography ( 15 ) liquid chromatography/tandem mass spectrometry assay . Samples also analyze ICG clearance lidocaine hydrochloride metabolic capacity fluorescent polarization immunoassay . After completion study therapy , patient follow periodically .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced solid tumor Any histology allow Refractory standard therapy OR standard therapy exist Previously untreated nonsmall cell lung cancer allow , provide abnormal liver function present , define moderate ( group 3 ) severe ( group 4 ) Measurable disease require Present measurable disease require baseline measurement within 4 week study entry Patients acute hepatitis viral drug etiology recover stable baseline prior study therapy History brain metastasis allow , provide follow criterion meet : Metastasis control radiotherapy surgery Patient currently corticosteroids Neurologic status stable PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Life expectancy ≥ 2 month ANC = 1,500/mm³ Platelet count = 100,000/mm³ Hemoglobin = 10 g/dL ( transfusion level allow ) Creatinine &lt; 1.5 mg/dL OR creatinine clearance &gt; 60 mL/ min Patients EKG evidence first seconddegree AV block leave right bundle branch block ineligible lidocaine bolus , may otherwise treat protocol Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No concurrent illness ( e.g. , cardiovascular , pulmonary , central nervous system ) poorly control severity investigator deem unwise enter patient protocol Must ability comply study treatment require test Obstructive jaundice require drainage procedure prior study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics Recovered prior therapy At least 3 week since prior chemotherapy ( 6 week mitomycin nitrosourea therapy ) No prior radiotherapy &gt; 30 % bone marrow standard adjuvant pelvic radiotherapy rectal cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>recurrent non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>stage IV non-small cell lung cancer</keyword>
</DOC>